Chapter Fourteen – Biomarkers in Preeclampsia

[1]  D. Wright,et al.  Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation. , 2016, American journal of obstetrics and gynecology.

[2]  S. Salahuddin,et al.  Sequential plasma angiogenic factors levels in women with suspected preeclampsia. , 2016, American journal of obstetrics and gynecology.

[3]  S. Karumanchi.  Angiogenic Factors in Preeclampsia: From Diagnosis to Therapy. , 2016, Hypertension.

[4]  R. van der Does,et al.  Influence of the sFlt-1/PlGF Ratio on Clinical Decision-Making in Women with Suspected Preeclampsia , 2016, PloS one.

[5]  A. Park,et al.  Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies , 2016, British Medical Journal.

[6]  S. Brennecke,et al.  Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. , 2016, The New England journal of medicine.

[7]  J. Haddow,et al.  Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia , 2015, Prenatal diagnosis.

[8]  C. Glabe,et al.  Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia , 2014, Science Translational Medicine.

[9]  J. Grande,et al.  Advances in the pathophysiology of pre-eclampsia and related podocyte injury ADDENDUM , 2014, Kidney international.

[10]  S. Karumanchi,et al.  Pre-eclampsia and cardiovascular disease. , 2014, Cardiovascular research.

[11]  H. Zeisler,et al.  New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia , 2014, Hypertension.

[12]  R. Romero,et al.  Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study , 2014, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[13]  D. Chou,et al.  Global and regional estimates of preeclampsia and eclampsia: a systematic review. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[14]  G. Saade,et al.  Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre‐eclampsia in a low‐risk nulliparous patient population? , 2013, BJOG: an International Journal of Obstetrics and Gynaecology.

[15]  R. Romero,et al.  Preeclampsia: a link between trophoblast dysregulation and an antiangiogenic state. , 2013, The Journal of clinical investigation.

[16]  R. Romero,et al.  Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. , 2013, American journal of obstetrics and gynecology.

[17]  Samuel Parry,et al.  Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. , 2012, American journal of obstetrics and gynecology.

[18]  S. Maynard,et al.  Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[19]  R. Riley,et al.  Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[20]  W. Cheng,et al.  Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy , 2012, Nature.

[21]  V. Sharma,et al.  Angiogenic Factors in Superimposed Preeclampsia: A Longitudinal Study of Women With Chronic Hypertension During Pregnancy , 2012, Hypertension.

[22]  K. Lim,et al.  Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia , 2012, Circulation.

[23]  R. Levine,et al.  Preeclampsia, a Disease of the Maternal Endothelium: The Role of Antiangiogenic Factors and Implications for Later Cardiovascular Disease , 2011, Circulation.

[24]  Marie Brown,et al.  Robust Early Pregnancy Prediction of Later Preeclampsia Using Metabolomic Biomarkers , 2010, Hypertension.

[25]  A. Hingorani,et al.  Prospective Study of Placental Angiogenic Factors and Maternal Vascular Function Before and After Preeclampsia and Gestational Hypertension , 2010, Circulation.

[26]  H. Russcher,et al.  Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. , 2010, Clinical biochemistry.

[27]  Mitsuaki Suzuki,et al.  Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia , 2010, Hypertension Research.

[28]  J. Dudenhausen,et al.  An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. , 2010, American journal of obstetrics and gynecology.

[29]  E. Gratacós,et al.  Does pre‐eclampsia influence fetal cardiovascular function in early‐onset intrauterine growth restriction? , 2009, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[30]  K. Nicolaides,et al.  Maternal serum placental protein 13 at 11–13 weeks of gestation in preeclampsia , 2009, Prenatal diagnosis.

[31]  D. Kell,et al.  Changes in the metabolic footprint of placental explant-conditioned culture medium identifies metabolic disturbances related to hypoxia and pre-eclampsia. , 2009, Placenta.

[32]  R. Romero,et al.  A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia , 2009, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[33]  L. Vatten,et al.  Hypertensive Disorders in Pregnancy and Subsequently Measured Cardiovascular Risk Factors , 2009, Obstetrics and gynecology.

[34]  K. Nicolaides,et al.  First-trimester maternal plasma cell-free fetal DNA and preeclampsia. , 2009, American journal of obstetrics and gynecology.

[35]  R. Drouin,et al.  Fetal-maternal exchange of multipotent stem/progenitor cells: microchimerism in diagnosis and disease. , 2009, Trends in molecular medicine.

[36]  F. Corrado,et al.  First trimester serum PAPP‐A and NGAL in the prediction of late‐onset pre‐eclampsia , 2009, Prenatal diagnosis.

[37]  T. Okai,et al.  Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop preeclampsia later in pregnancy: implications for screening , 2009, Prenatal diagnosis.

[38]  T. Takizawa,et al.  Human Villous Trophoblasts Express and Secrete Placenta-Specific MicroRNAs into Maternal Circulation via Exosomes1 , 2009, Biology of reproduction.

[39]  J. Olsen,et al.  Health of children born to mothers who had preeclampsia: a population-based cohort study. , 2009, American journal of obstetrics and gynecology.

[40]  Asma Khalil,et al.  First trimester maternal serum placental protein 13 for the prediction of pre‐eclampsia in women with a priori high risk , 2009, Prenatal diagnosis.

[41]  L. Christenson,et al.  Role of Dicer in female fertility , 2009, Trends in Endocrinology & Metabolism.

[42]  Steven H. Wu,et al.  A proteomic approach identifies early pregnancy biomarkers for preeclampsia: Novel linkages between a predisposition to preeclampsia and cardiovascular disease , 2009, Proteomics.

[43]  Lelia Duley,et al.  The global impact of pre-eclampsia and eclampsia. , 2009, Seminars in perinatology.

[44]  T. Han,et al.  Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. , 2009, American journal of obstetrics and gynecology.

[45]  Yasodha Natkunam,et al.  Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens , 2009, Nature Medicine.

[46]  S. Y. Park,et al.  Soluble endoglin and transforming growth factor‐β1 in women who subsequently developed preeclampsia , 2009, Prenatal diagnosis.

[47]  Kypros H Nicolaides,et al.  First-Trimester Prediction of Hypertensive Disorders in Pregnancy , 2009, Hypertension.

[48]  G. Acharya,et al.  Differential placental gene expression in severe preeclampsia. , 2009, Placenta.

[49]  B. Sibai,et al.  Diagnosis and management of atypical preeclampsia-eclampsia. , 2009, American journal of obstetrics and gynecology.

[50]  K. Nicolaides,et al.  First trimester urinary placental growth factor and development of pre‐eclampsia , 2009, BJOG : an international journal of obstetrics and gynaecology.

[51]  T. Okai,et al.  Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma. , 2009, American journal of obstetrics and gynecology.

[52]  J. Eriksson,et al.  Pre-Eclampsia Is Associated With Increased Risk of Stroke in the Adult Offspring: The Helsinki Birth Cohort Study , 2009, Stroke.

[53]  D. Maddocks,et al.  The SAFE project: towards non-invasive prenatal diagnosis. , 2009, Biochemical Society transactions.

[54]  A. Coomarasamy,et al.  Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review , 2009, BMC medicine.

[55]  Peipei Ping,et al.  Getting to the heart of proteomics. , 2009, The New England journal of medicine.

[56]  James Lyons-Weiler,et al.  Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. , 2009, Placenta.

[57]  Peng-Yuan Yang,et al.  Analysis of expression and comparative profile of normal placental tissue proteins and those in preeclampsia patients using proteomic approaches. , 2008, Analytica chimica acta.

[58]  L. Dodds,et al.  Low levels of maternal serum PAPP‐A in early pregnancy and the risk of adverse outcomes , 2008, Prenatal diagnosis.

[59]  G. Saade,et al.  Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. , 2008, American journal of obstetrics and gynecology.

[60]  H. Meiri,et al.  Placental protein 13 as an early marker for pre‐eclampsia: a prospective longitudinal study * , 2008, BJOG : an international journal of obstetrics and gynaecology.

[61]  E. Steegers,et al.  Severe, very early onset preeclampsia: subsequent pregnancies and future parental cardiovascular health. , 2008, European journal of obstetrics, gynecology, and reproductive biology.

[62]  M. Disatnik,et al.  Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the Heart , 2008, Science.

[63]  R. Levine,et al.  Circulating soluble endoglin and placental abruption , 2008, Prenatal diagnosis.

[64]  B. Sibai,et al.  Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? , 2008, American journal of obstetrics and gynecology.

[65]  B. Huppertz,et al.  Longitudinal Determination of Serum Placental Protein 13 during Development of Preeclampsia , 2008, Fetal Diagnosis and Therapy.

[66]  T. Leivestad,et al.  Preeclampsia and the risk of end-stage renal disease. , 2008, The New England journal of medicine.

[67]  H. Cuckle,et al.  First-trimester maternal serum PP13 in the risk assessment for preeclampsia. , 2008, American journal of obstetrics and gynecology.

[68]  F. Corrado,et al.  Endoglin, PlGF and sFlt‐1 as markers for predicting pre‐eclampsia , 2008, Acta obstetricia et gynecologica Scandinavica.

[69]  D. Kell,et al.  Analysis of the metabolic footprint and tissue metabolome of placental villous explants cultured at different oxygen tensions reveals novel redox biomarkers. , 2008, Placenta.

[70]  S. Karumanchi,et al.  Putting pressure on pre-eclampsia , 2008, Nature Medicine.

[71]  A. Diab,et al.  Angiogenic factors for the prediction of pre‐eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry , 2008, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[72]  D. Kell,et al.  Detection and Identification of Novel Metabolomic Biomarkers in Preeclampsia , 2008, Reproductive Sciences.

[73]  S. Y. Park,et al.  Effective Prediction of Preeclampsia by a Combined Ratio of Angiogenesis-Related Factors , 2008, Obstetrics and gynecology.

[74]  Mark E. Williams,et al.  Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[75]  E. Norwitz,et al.  Identification of Proteomic Biomarkers of Preeclampsia in Amniotic Fluid Using SELDI-TOF Mass Spectrometry , 2008, Reproductive Sciences.

[76]  R. Liston,et al.  Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review , 2008, BMJ : British Medical Journal.

[77]  Aeilko H. Zwinderman,et al.  Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis , 2008, Canadian Medical Association Journal.

[78]  T. Leung,et al.  Detection and characterization of placental microRNAs in maternal plasma. , 2008, Clinical chemistry.

[79]  N. Wessel,et al.  Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. , 2008, American journal of obstetrics and gynecology.

[80]  Saroj Saigal,et al.  An overview of mortality and sequelae of preterm birth from infancy to adulthood , 2008, The Lancet.

[81]  Wenjiang J. Fu,et al.  The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age , 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[82]  R. Romero,et al.  The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation , 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[83]  K. Nicolaides,et al.  Low levels of maternal serum PAPP‐A in the first trimester and the risk of pre‐eclampsia , 2008, Prenatal diagnosis.

[84]  Wenjiang J. Fu,et al.  A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate , 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[85]  D. Tsui,et al.  Quantitative aberrations of hypermethylated RASSF1A gene sequences in maternal plasma in pre‐eclampsia , 2007, Prenatal diagnosis.

[86]  T. Okai,et al.  Placenta-Derived, Cellular Messenger RNA Expression in the Maternal Blood of Preeclamptic Women , 2007, Obstetrics and gynecology.

[87]  A. Hingorani,et al.  Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[88]  S. Crawford,et al.  Angiogenic factors for the prediction of preeclampsia in high-risk women. , 2007, American journal of obstetrics and gynecology.

[89]  S. Karumanchi,et al.  The glomerular injury of preeclampsia. , 2007, Journal of the American Society of Nephrology : JASN.

[90]  M. Wolf,et al.  First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. , 2007, American journal of obstetrics and gynecology.

[91]  R. Levine,et al.  Sequential Changes in Antiangiogenic Factors in Early Pregnancy and Risk of Developing Preeclampsia , 2007 .

[92]  K. Lim,et al.  Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. , 2007, American journal of obstetrics and gynecology.

[93]  W. Cho,et al.  Oncoproteomics: current trends and future perspectives , 2007, Expert review of proteomics.

[94]  S. Karumanchi,et al.  Pre-Eclampsia: Clinical Manifestations and Molecular Mechanisms , 2007, Nephron Clinical Practice.

[95]  O. Mäkitie,et al.  Glucose regulation in young adults with very low birth weight. , 2007, The New England journal of medicine.

[96]  H. Kurahashi,et al.  Microarray analysis of differentially expressed fetal genes in placental tissue derived from early and late onset severe pre-eclampsia. , 2007, Placenta.

[97]  K. Bailey,et al.  Urinary podocyte excretion as a marker for preeclampsia. , 2007, American journal of obstetrics and gynecology.

[98]  A. Baschat,et al.  Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. , 2007, American journal of perinatology.

[99]  N. Wessel,et al.  Predictive Value of Maternal Angiogenic Factors in Second Trimester Pregnancies With Abnormal Uterine Perfusion , 2007, Hypertension.

[100]  R. Romero,et al.  Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. , 2007, American journal of obstetrics and gynecology.

[101]  S. Drăghici,et al.  BASIC SCIENCE: OBSTETRICS , 2022 .

[102]  L. Vatten,et al.  Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. , 2007, American journal of obstetrics and gynecology.

[103]  K. Spencer,et al.  Second‐trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre‐eclampsia , 2007, Prenatal diagnosis.

[104]  K. Spencer,et al.  First‐trimester maternal serum PP‐13, PAPP‐A and second‐trimester uterine artery Doppler pulsatility index as markers of pre‐eclampsia , 2007, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[105]  J. O’Leary,et al.  Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre‐eclampsia , 2007, Prenatal diagnosis.

[106]  E. Chien,et al.  Cytomegalovirus-Induced Mirror Syndrome Associated With Elevated Levels of Circulating Antiangiogenic Factors , 2007, Obstetrics and gynecology.

[107]  R. Romero,et al.  Unexplained fetal death: Another anti-angiogenic state , 2007, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[108]  W. Holzgreve,et al.  Comparison of activin A and cell‐free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia , 2006, Prenatal diagnosis.

[109]  T. Okai,et al.  Quantitative distribution of a panel of circulating mRNA in preeclampsia versus controls , 2006, Prenatal diagnosis.

[110]  Peipei Ping,et al.  Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. , 2006, Journal of the American College of Cardiology.

[111]  B. Sibai,et al.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.

[112]  John Quackenbush.  Microarray analysis and tumor classification. , 2006, The New England journal of medicine.

[113]  T. Libermann,et al.  Soluble endoglin contributes to the pathogenesis of preeclampsia , 2006, Nature Medicine.

[114]  A. Coomarasamy,et al.  Accuracy of serum uric acid in predicting complications of pre‐eclampsia: a systematic review , 2006, BJOG : an international journal of obstetrics and gynaecology.

[115]  E. Vanninen,et al.  Maternal Preeclampsia Predicts Elevated Blood Pressure in 12-Year-Old Children: Evaluation by Ambulatory Blood Pressure Monitoring , 2006, Pediatric Research.

[116]  V. Jha,et al.  Low urinary placental growth factor is a marker of pre-eclampsia. , 2006, Kidney international.

[117]  K. Nicolaides,et al.  A novel approach to first‐trimester screening for early pre‐eclampsia combining serum PP‐13 and Doppler ultrasound , 2005, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[118]  Douglas B. Kell,et al.  Novel biomarkers for pre-eclampsia detected using metabolomics and machine learning , 2005, Metabolomics.

[119]  S. Daly,et al.  Increased fetal RhD gene in the maternal circulation in early pregnancy is associated with an increased risk of pre‐eclampsia , 2005, BJOG : an international journal of obstetrics and gynaecology.

[120]  Kirsten Duckitt,et al.  Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies , 2005, BMJ : British Medical Journal.

[121]  B. Sibai.  Diagnosis, prevention, and management of eclampsia. , 2005, Obstetrics and gynecology.

[122]  A. LaCroix,et al.  Risk Factors Associated with Acute Pyelonephritis in Healthy Women , 2005, Annals of Internal Medicine.

[123]  R. Romero,et al.  Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia , 2005, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[124]  D. Maharaj,et al.  The Accuracy of Urine Dipsticks as a Screening Test for Proteinuria in Hypertensive Disorders of Pregnancy , 2005, Hypertension in pregnancy.

[125]  E. Norwitz,et al.  Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. , 2004, American journal of obstetrics and gynecology.

[126]  P. Hofman,et al.  Premature birth and later insulin resistance. , 2004, The New England journal of medicine.

[127]  N. Berkane,et al.  Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. , 2004, Clinical chemistry.

[128]  T. Okai,et al.  Total cell‐free DNA (β‐globin gene) distribution in maternal plasma at the second trimester: a new prospective for preeclampsia screening , 2004, Prenatal diagnosis.

[129]  C. Baykal,et al.  Random Urine Protein-Creatinine Ratio to Predict Proteinuria in New-Onset Mild Hypertension in Late Pregnancy , 2004, Obstetrics and gynecology.

[130]  S. Daly,et al.  Increased fetal DNA in the maternal circulation in early pregnancy is associated with an increased risk of preeclampsia. , 2004, American journal of obstetrics and gynecology.

[131]  A. Admon,et al.  Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. , 2004, Placenta.

[132]  B. Sibai.  HIGH-RISK PREGNANCY SERIES: AN EXPERT’S VIEW Diagnosis, Controversies, and Management of the Syndrome of Hemolysis, Elevated Liver Enzymes, and Low Platelet Count , 2004 .

[133]  E. Schisterman,et al.  Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. , 2004, American journal of obstetrics and gynecology.

[134]  Hans Bohn,et al.  Functional analyses of placental protein 13/galectin-13. , 2004, European journal of biochemistry.

[135]  T. Arinami,et al.  Proteome analysis reveals elevated serum levels of clusterin in patients with preeclampsia , 2004, Proteomics.

[136]  Robert N. Taylor,et al.  First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. , 2004, The Journal of clinical endocrinology and metabolism.

[137]  T. Spector,et al.  Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.

[138]  Y. Taketani,et al.  Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. , 2003, The Journal of clinical endocrinology and metabolism.

[139]  R. Chiu,et al.  mRNA of placental origin is readily detectable in maternal plasma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[140]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[141]  L. Giudice,et al.  Identification and regulation of the IGFBP-4 protease and its physiological inhibitor in human trophoblasts and endometrial stroma: evidence for paracrine regulation of IGF-II bioavailability in the placental bed during human implantation. , 2002, The Journal of clinical endocrinology and metabolism.

[142]  R. T. Lie,et al.  The interval between pregnancies and the risk of preeclampsia. , 2002, The New England journal of medicine.

[143]  W. Holzgreve,et al.  THE LEVELS OF CIRCULATORY FETAL DNA IN MATERNAL PLASMA ARE ELEVATED PRIOR TO THE ONSET OF PREECLAMPSIA , 2002 .

[144]  R. T. Lie,et al.  Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. , 2001, BMJ : British Medical Journal.

[145]  H. Bohn,et al.  Homology modelling and molecular dynamics studies of human placental tissue protein 13 (galectin-13). , 2001, Protein engineering.

[146]  T. Lau,et al.  Circulating Fetal RNA in Maternal Plasma , 2001, Annals of the New York Academy of Sciences.

[147]  H. Ho,et al.  Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. , 2001, American journal of obstetrics and gynecology.

[148]  J. Higgins,et al.  Blood-pressure measurement and classification in pregnancy , 2001, The Lancet.

[149]  A. Evangelou,et al.  Adult cardiovascular risk factors in premature babies , 2000, The Lancet.

[150]  K. Nicolaides,et al.  Increased fetal erythroblasts in women who subsequently develop pre-eclampsia. , 2000, Human reproduction.

[151]  J R Yates,et al.  The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[152]  V. Han,et al.  Autocrine-paracrine regulation of human trophoblast invasiveness by insulin-like growth factor (IGF)-II and IGF-binding protein (IGFBP)-1. , 1998, Experimental cell research.

[153]  K. Lim,et al.  The clinical utility of serum uric acid measurements in hypertensive diseases of pregnancy. , 1998, American journal of obstetrics and gynecology.

[154]  I. Sargent,et al.  Presence of fetal DNA in maternal plasma and serum , 1997, The Lancet.

[155]  H. Nisell.  A comparison of the inactive urinary kallikrein: creatinine ratio and the angiotensin sensitivity test for the prediction of pre-eclampsia. , 1996 .

[156]  B. Higgins,et al.  Early prediction of pre‐eclampsia by measurement of kallikrein and creatinine on a random urine sample , 1996 .

[157]  R. Berkowitz,et al.  The Changing Clinical Presentation of Complete Molar Pregnancy , 1995, Obstetrics and gynecology.

[158]  H. Nisell,et al.  Blood pressure and renal function seven years after pregnancy complicated by hypertension , 1995, British journal of obstetrics and gynaecology.

[159]  A. Noble,et al.  Ail Instructive Case of Abdominal Pregnaney , 1995 .

[160]  D. Stevenson,et al.  Pre‐eclampsia and offspring's blood pressure, cognitive ability and physical development at 17‐years‐of‐age , 1991, British journal of obstetrics and gynaecology.

[161]  T. Musci,et al.  Preeclampsia: an endothelial cell disorder. , 1989, American journal of obstetrics and gynecology.

[162]  L. Weinstein.  Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. , 1982, American journal of obstetrics and gynecology.

[163]  F. Conte,et al.  Practical and theoretical implications of fetal-maternal lymphocyte transfer. , 1969, Lancet.

[164]  D. Wright,et al.  Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. , 2016, American journal of obstetrics and gynecology.

[165]  Mimi Y. Kim,et al.  Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. , 2016, American journal of obstetrics and gynecology.

[166]  G. Piccoli,et al.  Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. , 2013, Kidney international.

[167]  W. Holzgreve,et al.  The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. , 2012, American journal of obstetrics and gynecology.

[168]  B. Sibai,et al.  Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. , 2010, American journal of obstetrics and gynecology.

[169]  Y. Lo,et al.  A microarray approach for systematic identification of placental-derived RNA markers in maternal plasma. , 2008, Methods in molecular biology.

[170]  J. Kleijnen,et al.  Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. , 2008, BMC pregnancy and childbirth.

[171]  G. ter Riet,et al.  Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. , 2008, Health technology assessment.

[172]  R. Chiu,et al.  Innovations: Prenatal diagnosis: progress through plasma nucleic acids , 2007, Nature Reviews Genetics.

[173]  R. Chiu,et al.  The biology and diagnostic applications of fetal DNA and RNA in maternal plasma. , 2004, Current topics in developmental biology.

[174]  Robert N. Taylor,et al.  Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. , 2003, American journal of obstetrics and gynecology.

[175]  C. Sohn,et al.  Elevation in erythroblast count in maternal blood before the onset of preeclampsia. , 2001, American journal of obstetrics and gynecology.